Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aratana Therapeutics has entered into a licence agreement with Japan-based drug discovery and development company, RaQualia Pharma to develop two compounds for use in animal health. The compounds are part of the RaQualia's human clinical development portfolio.
Subscribe to our email newsletter
Under the agreement, Aratana will be granted global rights to develop and commercialise the licensed animal health products.
Proof of efficacy in human studies has been achieved with the first compound, a selective EP-4 antagonist, and efficacy has been demonstrated in animal models for several conditions such as autoimmune/inflammatory diseases, cancer and pain.
Proof of efficacy in human studies has been achieved with the second compound, a selective Ghrelin agonist, which also showed efficacy in animal models for treatment of cachexia and frailty.
Aratana CEO Linda Rhodes said the first development programmes have the potential to improve treatment options for two important related animal diseases.
In exchange for the global rights, RaQualia will receive an upfront payment, development milestones and royalties on global sales achieved after the drug is launched.
Financial terms of the license agreement had not been disclosed.